|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/08/18 Sarepta Therapeutics, Inc. 10-Q 6/30/18 85:10M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Srpt Q2 2018 10-Q HTML 978K
2: EX-2.1 Plan of Acquisition, Reorganization, Arrangement, HTML 627K
Liquidation or Succession
3: EX-10.1 Material Contract HTML 139K
4: EX-10.2 Material Contract HTML 179K
5: EX-10.3 Material Contract HTML 73K
6: EX-10.4 Material Contract HTML 39K
7: EX-10.5 Material Contract HTML 56K
8: EX-10.6 Material Contract HTML 30K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
19: R1 Document and Entity Information HTML 45K
20: R2 Condensed Consolidated Balance Sheets HTML 104K
21: R3 Condensed Consolidated Balance Sheets HTML 48K
(Parenthetical)
22: R4 Condensed Consolidated Statements of Operations HTML 94K
and Comprehensive Loss
23: R5 Condensed Consolidated Statements of Cash Flows HTML 138K
24: R6 Organization and Nature of Business HTML 33K
25: R7 Summary of Significant Accounting Policies and HTML 52K
Recent Accounting Pronouncements
26: R8 Collaboration, License and Manufacturing HTML 37K
Agreements
27: R9 Fair Value Measurements HTML 138K
28: R10 Cash, Cash Equivalents and Marketable Securities HTML 203K
29: R11 Accounts Receivable and Reserves for Product Sales HTML 102K
30: R12 Inventory HTML 47K
31: R13 Other Current Assets and Other Non-Current Assets HTML 95K
32: R14 Accrued Expenses HTML 76K
33: R15 Indebtedness HTML 60K
34: R16 Restructuring HTML 52K
35: R17 Stock-Based Compensation HTML 153K
36: R18 Other Income and Loss HTML 74K
37: R19 Income Taxes HTML 28K
38: R20 Net (Loss) Earnings Per Share HTML 91K
39: R21 Commitments and Contingencies HTML 77K
40: R22 Subsequent Events HTML 28K
41: R23 Summary of Significant Accounting Policies and HTML 63K
Recent Accounting Pronouncements (Policies)
42: R24 Fair Value Measurements (Tables) HTML 134K
43: R25 Cash, Cash Equivalents and Marketable Securities HTML 203K
(Tables)
44: R26 Accounts Receivable and Reserves for Product Sales HTML 103K
(Tables)
45: R27 Inventory (Tables) HTML 47K
46: R28 Other Current Assets and Other Non-Current Assets HTML 97K
(Tables)
47: R29 Accrued Expenses (Tables) HTML 75K
48: R30 Indebtedness (Tables) HTML 57K
49: R31 Restructuring (Tables) HTML 50K
50: R32 Stock-Based Compensation (Tables) HTML 158K
51: R33 Other Income and Loss (Tables) HTML 74K
52: R34 Net (Loss) Earnings Per Share (Tables) HTML 91K
53: R35 Commitments and Contingencies (Tables) HTML 61K
54: R36 Organization and Nature of Business - Additional HTML 37K
Information (Detail)
55: R37 Summary of Significant Accounting Policies and HTML 50K
Recent Accounting Pronouncements - Additional
Information (Detail)
56: R38 Collaboration, License and Manufacturing HTML 77K
Agreements - Additional Information (Detail)
57: R39 Assets Measured and Carried at Fair Value (Detail) HTML 50K
58: R40 Summary of Company Financial Assets with HTML 34K
Maturities of Less Than 90 Days Included in Cash
Equivalents (Detail)
59: R41 Cash, Cash Equivalents and Marketable Securities - HTML 26K
Additional Information (Detail)
60: R42 Summary of Company Cash, Cash Equivalents and HTML 62K
Short-term Investments (Detail)
61: R43 Summary of Components of Accounts Receivable HTML 32K
(Detail)
62: R44 Summary of Change in Reserves for Discounts and HTML 43K
Allowances (Detail)
63: R45 Summary of Total Reserves Included in Consolidated HTML 31K
Balance Sheets (Detail)
64: R46 Inventory - Summary of Components of Inventory HTML 36K
(Detail)
65: R47 Summary of Other Current Assets (Detail) HTML 44K
66: R48 Summary of Other Non-current Assets (Detail) HTML 41K
67: R49 Summary of Accrued Expenses (Detail) HTML 55K
68: R50 Indebtedness - Additional Information (Detail) HTML 105K
69: R51 Indebtedness - Summary of Debt Facilities (Detail) HTML 44K
70: R52 Restructuring - Additional Information (Detail) HTML 41K
71: R53 Summary of Restructuring Reserve (Detail) HTML 36K
72: R54 Summary of Stock Awards Granted (Detail) HTML 42K
73: R55 Stock Based Compensation - Additional Information HTML 28K
(Detail)
74: R56 Summary of Stock-Based Compensation Expense by HTML 34K
Function Included within Condensed Consolidated
Statements of Operations and Comprehensive Loss
(Detail)
75: R57 Summary of Stock-Based Compensation Expense by HTML 36K
Grant Type Included within Condensed Consolidated
Statements of Operations and Comprehensive Loss
(Detail)
76: R58 Summary of Other Income and Loss (Detail) HTML 39K
77: R59 Basic and Diluted Net (Loss) Earnings Per Share HTML 50K
(Detail)
78: R60 Basic and Diluted Net (Loss) Earnings Per Share HTML 27K
(Parenthetical) (Detail)
79: R61 Commitments and Contingencies - Additional HTML 30K
Information (Detail)
80: R62 Summary of Aggregate Non-Cancelable Future Minimum HTML 43K
Payments under Company's Leases (Detail)
81: R63 Summary of Aggregate Non-Cancelable Contractual HTML 37K
Obligations Arising from Manufacturing Obligations
(Detail)
82: R64 Subsequent Events - Additional Information HTML 33K
(Detail)
84: XML IDEA XML File -- Filing Summary XML 144K
83: EXCEL IDEA Workbook of Financial Reports XLSX 74K
13: EX-101.INS XBRL Instance -- srpt-20180630 XML 2.39M
15: EX-101.CAL XBRL Calculations -- srpt-20180630_cal XML 197K
16: EX-101.DEF XBRL Definitions -- srpt-20180630_def XML 317K
17: EX-101.LAB XBRL Labels -- srpt-20180630_lab XML 979K
18: EX-101.PRE XBRL Presentations -- srpt-20180630_pre XML 705K
14: EX-101.SCH XBRL Schema -- srpt-20180630 XSD 166K
85: ZIP XBRL Zipped Folder -- 0001564590-18-020534-xbrl Zip 143K
CERTIFICATION
I, Douglas S. Ingram, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Sarepta Therapeutics, Inc., (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
|
|
||
|
|
|
|
|
|
|
President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/8/18 | 4 | ||
| For Period end: | 6/30/18 | 10-Q/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 2/28/24 Sarepta Therapeutics, Inc. 10-K 12/31/23 119:18M Donnelley … Solutions/FA 8/02/23 Sarepta Therapeutics, Inc. S-8 8/02/23 4:69K Donnelley … Solutions/FA 2/28/23 Sarepta Therapeutics, Inc. 10-K 12/31/22 119:23M Donnelley … Solutions/FA 8/02/22 Sarepta Therapeutics, Inc. S-8 8/02/22 4:58K Donnelley … Solutions/FA 3/01/22 Sarepta Therapeutics, Inc. 10-K 12/31/21 121:20M Donnelley … Solutions/FA 3/01/21 Sarepta Therapeutics, Inc. 10-K 12/31/20 124:22M ActiveDisclosure/FA 8/05/20 Sarepta Therapeutics, Inc. S-8 8/05/20 3:151K ActiveDisclosure/FA |